R&D | Cutting-edge science and innovative research

News

AZ makes case for hypophosphatasia drug after phase 3 miss

AstraZeneca has high sales expectations for HPP therapy efzimfotase alfa, but will the data support the broad label needed to unlock its potential?

News

B&W image on a man peering out between his fingers, hands covering his face

MSD data reveal undercuts eye drug remigromig's potential

In its decanting of the BRUNELLO trial of remigromig for diabetic macular oedema, MSD seems to have left observers contemplating a glass half empty.

News

Lilly's Zepbound enhances Taltz efficacy in psoriasis study

A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.

News

Iambic prices its IPO, seeking to raise up to $160m

AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.

News

Female tennis player goes to serve for the match point

Matchpoint scores $150m for I&I drugs, and other financings

Matchpoint has closed a $150m round for its immunology-focused covalent drugs, with KymaThera, Rouge, Sensible Bio, and Arboretum also raising funds.

News

Theravance axes staff as lead pipeline drug flunks phase 3 t...

Theravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in a phase 3 trial, cutting 75% of its workforce.

News

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

First subject dosed in psilocybin trial for rare headache di...

The first patient has received a low dose of Beckley Psytech's psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare

News

Rome Therapeutics raises $77m for junk DNA-targeting drugs

Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as 'junk' – for hidden treasure.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

AZ makes case for hypophosphatasia drug after phase 3 miss

AstraZeneca has high sales expectations for HPP therapy efzimfotase alfa, but will the data support the broad label needed to unlock its potential?

News

MSD data reveal undercuts eye drug remigromig's potential

In its decanting of the BRUNELLO trial of remigromig for diabetic macular oedema, MSD seems to have left observers contemplating a glass half empty.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Changing Faces: Pharma and biotech hires, September 2026

There was plenty of movement at the top of pharma and biotech in September, with leadership changes spanning some of the industry’s biggest names.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

R&D

Digital representation of sepsis bacteria attacking heart

The hidden pandemic within the pandemic: How COVID-19 impact...

Why sepsis readiness – equipment, supply chains, surveillance, and public awareness – needs to be treated as core pandemic infrastructure.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

R&D

two healthcare professionals looking at chart

Sponsored

Decentralisation by design: Bringing the trial closer withou...

In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.